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Abstract
Evidence based clinical guidelines are implemented to treat patients efficiently that include efficacy, tolerability but also health
economic considerations. This is of particular relevance to the new direct acting antiviral agents that have revolutionized treatment of
chronic hepatitis C. For hepatitis C genotypes 2/3 interferon free treatment is already available with sofosbuvir plus ribavirin. However,
treatment with sofosbuvir-based regimens is 10–20 times more expensive compared to pegylated interferon alfa and ribavirin
(PegIFN/RBV). It has to be discussed if PegIFN/RBV is still an option for easy to treat patients. We assessed the treatment of patients
with chronic hepatitis C genotypes 2/3 with PegIFN/RBV in a real world setting according to the latest German guidelines. Overall,
1006 patients were recruited into a prospective patient registry with 959 having started treatment. The intention-to-treat analysis
showed poor SVR (GT2 61%, GT3 47%) while patients with adherence had excellent SVR in the per protocol analysis (GT2 96%, GT3
90%). According to guidelines, 283 patients were candidates for shorter treatment duration, namely a treatment of 16 weeks (baseline
HCV-RNA ,800.000 IU/mL, no cirrhosis and RVR). However, 65% of these easy to treat patients have been treated longer than
recommended that resulted in higher costs but not higher SVR rates. In conclusion, treatment with PegIFN/RBV in a real world setting
can be highly effective yet similar effective than PegIFN6 sofosbuvir/RBV in well-selected naı¨ve G2/3 patients. Full adherence to
guidelines could be further improved, because it would be important in the new era with DAA, especially to safe resources.
Citation: Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, et al. (2014) Treatment of Naı¨ve Patients with Chronic Hepatitis C Genotypes 2 and 3 with
Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. PLoS ONE 9(10): e108751. doi:10.1371/journal.pone.0108751
Editor: David R. Booth, University of Sydney, Australia
Received May 8, 2014; Accepted August 26, 2014; Published October 10, 2014
Copyright:  2014 Heidrich et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This registry was financially supported by MSD Sharp & Dohme GmbH (manufacturer of pegylated interferon alpha-2b) (http://www.msd.de/). The
protocol and the contracts did not intend to influence the decision to treat patients with pegylated interferon alpha-2b. The HepNet study house of the German
Liver Foundation, which was supported by the German Center for Infectious Disease Research (DZIF), coordinated and formally sponsored the registry. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Markus Cornberg has read the journal’s policy and the authors of this manuscript have the following competing interests: Benjamin
Heidrich: nothing to disclose; Steffen B. Wiegand: nothing to disclose; Peter Buggisch: Honoraria for consulting or speaking: Gilead, Roche, MSD, Janssen, BMS und
AbbVie; Holger Hinrichsen: nothing to disclose; Ralph Link: nothing to disclose; Bernd Mo¨ller: nothing to disclose; Klaus H. W. Bo¨ker: Honoraria for speaking: Bristol-
Myers-Squibb, Gilead, Roche Pharma, Merck (MSD Sharp & Dohme GmbH), Novartis; Janssen-Cilag, Gilead; Gerlinde Teuber: received financial support for advise and
talk from: Roche, MSD, Bristol-Myers Squibb, Janssen-Cilag, Gilead, AbbVie; Hartwig Klinker: received grants, Board membership fees and lecture fees from: AbbVie,
Boehringer, Bristol-Myers Squibb, Gilead, Glaxo-SmithKline, Hexal, Janssen-Cilag, MSD, Roche, and ViiV Healthcare; Elmar Zehnter: nothing to disclose; Uwe Naumann:
received financial support for research, advise and talk from: Roche, MSD, Bristol-Myers Squibb, Janssen-Cilag, Gilead, ViiV, AbbVie, Boehringer Ingelheim; Heiner W.
Busch: Honoraria for speaking: Gilead, Janssen-Cilag, MSD Sharp & Dohme, Roche, ViiV; Benjamin Maasoumy: Honoraria for consulting or speaking: Roche Pharma,
Roche Diagnostics, Abbott Molecular, Merck, MSD Sharp & Dohme, Janssen/Janssen TE, Fujirebio; Undine Baum: nothing to disclose; Svenja Hardtke: nothing to
disclose; Michael P. Manns: received financial compensation for consultancy and/or lecture activities from: Roche, Bristol Myers Squibb, Gilead, Boehringer Ingelheim,
Novartis, Merck, Janssen, Idenix and GlaxoSmithKline, and research grants from: Roche, Gilead, Novartis, Boehringer Ingelheim, Bristol Myers Squibb, Merck and
Janssen; Heiner Wedemeyer: Honoraria for consulting or speaking: Abbott, Abvie, Biolex, BMS, Boehringer Ingelheim, Gilead, ITS, JJ/Janssen-Cilag, Medgenics, Merck/
Schering-Plough, Novartis, Roche, Roche Diagnostics, Siemens, Transgene, ViiV and research grants: Abbott, BMS, Gilead, Merck, Novartis, Roche Diagnostics,
Siemens; Jo¨rg Petersen: Grant/Research Support: BMS, Novartis, Roche and Consultant/Advisor: Abbott, AbbVie, BMS, Boehringer, Gilead, GSK, Kedrion, Janssen,
Merck, MSD, Novartis, Roche and Sponsored lectures: Abbott, BMS, Boehringer, Gilead, Kedrion, Janssen, Merck, MSD, Novartis, Roche; Markus Cornberg: Lecture fees:
Bristol-Myers-Squibb, Boehringer Ingelheim, Gilead, Roche Pharma, Roche Diagnostics, Merck (MSD Sharp & Dohme GmbH), Novartis, Falk and research support:
Gilead, Roche Pharma, Roche Diagnostics, Merck (MSD Sharp & Dohme GmbH) and consultant fees: Abbvie, Boehringer Ingelheim, Gilead, Roche Pharma, Roche
Diagnostics, Merck (MSD Sharp & Dohme GmbH), Novartis. This registry was financially supported by MSD Sharp & Dohme GmbH (manufacturer of pegylated
interferon alpha-2b). The protocol and the contracts did not intend to influence the decision to treat patients with pegylated interferon alpha-2b. This does not alter
the authors’ adherence to PLOS ONE policies on sharing data and materials.
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e108751
* Email: Cornberg.Markus@mh-hannover.de
. These authors contributed equally to this work.
Introduction
More than 150 million people world-wide and 8–11 million
people in Europe are chronically infected with the hepatitis C virus
(HCV) [1,2]. Patients with chronic hepatitis C are at risk to
develop liver cirrhosis and hepatocellular carcinoma [3]. During
the last 15 years there has been an enormous achievement in the
diagnosis, management, and therapy of hepatitis C. Analysis of
HCV-genotypes (GT), quantification of HCV-RNA viral load,
and calculation of viral kinetics allow better management of
patients with chronic hepatitis C. The standard treatment until
recently consisted of pegylated interferon alpha (PegIFN) and
ribavirin (RBV) [4]. Since 2011, the first direct acting antiviral
agents (DAA) have been approved. The first generation protease
inhibitors boceprevir and telaprevir were only approved for
genotype 1 and combination with PegIFN and RBV was still
necessary because monotherapy resulted in rapid emergence of
drug resistance [5]. However, the availability of further DAA has
already revolutionized the treatment of chronic hepatitis C. The
main targets for DAA are the NS3/4A protease, NS5B polymerase
and the NS5A replication complex. Combinations of different
DAA from different classes will allow very potent treatments even
without PegIFN [6]. In particular, therapy of GT2/3 has changed
in 2014 with the approval of sofosbuvir (SOF). SOF is a new NS5B
polymerase inhibitor with pangenotypic efficacy and extensive
data were acquired in the treatment of GT2- and GT3-infected
patients, which were the basis for the approval for the first
interferon-free treatment of hepatitis C [7–9]. However, treatment
with PegIFN/RBV dual therapy may be still considered depend-
ing on the health care system, especially for easy-to-treat GT2/3
patients. Treatment with SOF/RBV therapy for 12 to 24 weeks or
SOF in combination PegIFN and RBV in HCV genotype 2 or 3
can be 10–20 times more expensive compared to PegIFN and
RBV treatment [10].
For Peg-IFN/RBV a fixed duration of treatment (24 weeks) has
been suggested [11], although the optimal results are likely to be
achieved when the duration of therapy is adjusted based on viral
kinetics. Many studies have investigated the reduction of treatment
duration for HCV GT2/3 to 16, 14, or even 12 weeks [12–14].
Overall, reducing the treatment duration to less than 24 weeks
increases the number of relapses. However, some HCV GT2/3
patients may indeed be treatable for 12–16 weeks if certain
prerequisites are fulfilled, especially the rapid virologic response
(RVR) by week 4 of therapy [15]. In addition to the RVR, the
specific HCV genotype and the baseline viral load are associated
with response [12]. Patients with low baseline viral load ,
800.000 IU/ml and RVR have high SVR rates.85% after 16
weeks, 14 weeks, or even 12 weeks of therapy. Reducing treatment
duration is not recommended for patients with advanced liver
fibrosis or cirrhosis, insulin resistance, diabetes mellitus or BMI.
30 kg/m2 [15]. Thus, recent clinical guidelines recommended that
naı¨ve patients with GT2/3 plus low viral load who achieve RVR
can be treated shortly, i.e. 16 weeks according to the German
Guidelines [15].
A major aim of this study was to find out if patients with GT2/3
were treated according to guidelines and if this treatment is
efficient. We also discussed the results in the context of the new
SOF-based treatment for GT2/3.
Materials and Methods
Patient population
The Competence Network for Viral Hepatitis in Germany
(HepNet) implemented a nationwide multicenter prospective
registry for naı¨ve patients chronically infected with hepatitis C
virus (HCV) genotype 2 and 3. MSD Merck Sharp & Dohme
sponsored the registry (financial sponsorship only). The inclusion
criteria (File S1) allowed treatment with both pegylated interferons
(PegIFN a2a, PegIFN a2b).
Between June 2008 and December 2012 a total of 1006 patients
were recruited in 72 centers in Germany. All patients at the age of
18 or older with chronic hepatitis C genotype 2 or 3 infection,
detectable plasma HCV RNA and positivity of anti-HCV
antibodies as well as no history of antiviral therapy were eligible
(Figure 1).
HCV RNA quantification
HCV RNA was assessed at baseline, week 4, 212, end of
treatment and 24 weeks after cessation of therapy. Samples were
tested locally with different assays and thresholds. The Cobas-
TaqMan assay with a lower limit of quantification (LoQ) of
15 IU/mL was used in 57%, the Abbott RealTime assay in 8%
with a LoQ of 12 IU/mL and the Roche Amplicor assay with
LoQ of 50 IU/mL in 5%. Additionally, in 24% the used assay was
not indicated and in 7% others or in-house assays with different
cut-offs were used. Assays were used according to manufacturer’s
instructions.
Laboratory results
Several Biochemical and hematological parameters at baseline
were assessed locally. Biochemical markers included alanine
aminotransferase (ALT), aspartate aminotransferase (AST), gam-
ma-glutamyltransferase (GGT) and alkaline phosphatase (ALP) as
well as bilirubin, creatinine and albumin. Hematological param-
eters included platelet counts and prothrombin time.
Definitions of response to therapy
Rapid virological response (RVR) was defined as HCV RNA
below 15 IU/mL at week 4 of treatment with pegylated interferon
alpha (PegIFN) and ribavirin (RBV), early virological response
(EVR) was defined as $2 log10 decrease from baseline in HCV
RNA or HCV RNA negativity at week 12; end of treatment
response (EOT) and sustained virological (SVR) were defined as
HCV RNA below detection limit at the end of treatment and 24
weeks after the end of treatment, respectively [15]. In the
intention-to-treat (ITT) analysis all patients with at least one dose
of PegIFN and RBV were included. Missing results for RVR and
SVR were considered as negative results. For the per-protocol (PP)
analysis, patients treated for at least 12 weeks and with available
results at week 4 and/or 24 weeks after end of therapy were
considered for each evaluation.
Definition of liver cirrhosis
Diagnosis of cirrhosis was either based on liver histology or non-
invasive methods such as ultrasound, FibroScan or biochemical
results. Liver cirrhosis in biopsies was defined as F4 in Metavir or
F5-6 in ISHAK. In addition, diagnosis of liver cirrhosis was based
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on ultrasound results assessed by the local physician. Liver stiffness
$12.5 kPa was considered as cirrhosis [16]. Patients with at least
two of the following criteria platelets ,100/nL, AST/ALT ratio.
1, bilirubin.1.5 ULN and albumin ,35 g/L fulfilled biochemical
assessment of cirrhosis. Individuals were considered having
cirrhosis if one of the definitions above was imbued.
Statistical analysis
For statistical analysis as well as for graphic design we used
SPSS, version 15.0.1 (November 2006, SPSS, Munich, Germany)
and GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA,
USA). Quantitative values are indicated in median and statistical
differences were assessed by using Student t test. In case of analysis
of qualitative data we used Chi square test. Differences between
clinical outcomes were determined using Cox regression analysis.
Differences were considered significant at p#0.05.
Ethical approval
Ethics committee at each participating institution approved the
non-interventional patient registry of the German Competence
Network for Viral Hepatitis (Hep-Net) and each patient signed a
written informed consent form. The registry has been performed
according to the World Medical Association Declaration of
Helsinki (http://www.wma.net/e/policy/b3.htm). The proce-
dures have been approved by the local ethics committee of the
Figure 1. Flow chart of patients recruited in the HCV genotype 2/3 registry.
doi:10.1371/journal.pone.0108751.g001
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Hannover Medical School (Vote No. 3860) and are in line with
German law.
Results
Between June 2008 and December 2012 a total of 1006 patients
were included. 959 patients received at least one dose of pegylated
interferon alfa (PegIFN) and ribavirin (RBV). Two out of three
patients were male with a median age of 43.8 years and BMI of
25.0 kg/m2. The majority of patients originated from Germany
and was infected with genotype (GT) 3. Hepatic steatosis was
present in about one-third of patients and cirrhosis was diagnosed
in 8.0% (Table 1, 2, and 3).
The Majority of patients received PegIFN-2b (n = 799; 83%)
whereas 122 patients were treated with PegIFN-2a. For the
remaining 38 patients the exact treatment regimen was not fully
specified. In 24 patients (3%) baseline HCV RNA levels were not
determined (Figure 1).
HCV RNA assays used for diagnosis and monitoring
Since our cohort consists of patients treated within a prospective
registry in a real world setting in multiple centers several different
HCV RNA assays were used. Overall, in the far majority of cases
the used assays were indicated (n = 765; 76%). Importantly, in 46
cases out of 765 (6%) in-house PCRs were used instead of
commercially available assays. Most of the patients (n = 691; 90%)
were monitored with very sensitive assays with limits of
quantification of 15 IU/mL. However, in 62 (8%) patients assays
with moderate sensitivity (LoQ 50 IU/mL) and in 8 (1%) patients
assays with low sensitivity (LoQ.50 IU/mL) were used.
Efficacy of treatment
The overall sustained virological response (SVR) was 49% in the
intention-to-treat (ITT) analysis and 91% in the per-protocol (PP)
analysis (Figure 2). Individuals with HCV GT2 had significantly
higher SVR rates than GT3 patients in the ITT and PP analysis,
respectively (ITT 61% vs. 48%; p = 0.0013; PP 96% vs. 90%;
p = 0.0479) (Figure 2).
Table 1. Baseline characteristics of all patients who started treatment with PegIFN/RBV.
Parameter* Value Range n=
Male [%] 65.7 n = 617/939
Age [years] 43.8610.6 20.1–81.8 n = 957
Weight [kg] 76.0616.9 40.0–162.0 n = 931
BMI [kg/m2] 25.064.8 15.2–57.7 n = 919
CoO Germany [%] 60.0 n = 538
CoO EE/USSR [%] 30.8 n = 276
CoO Mediterranen [%] 6.1 n = 55
CoO Others [%] 3.0 n = 27
Genotype 3 [%] 82.7 n = 769
HCV RNA [log10 IU/mL] 5.861.0 1.2–8.7 n = 934
ALT [U/L] 89.06107.7 11.0–1273.0 n = 909
Cirrhosis [%] 7.8 n = 75/959
Steatosis [%] 28.8 n = 225/782
doi:10.1371/journal.pone.0108751.t001
Table 2. Baseline characteristics of patients with HCV Genotype 2 who started treatment with PegIFN/RBV.
Parameter* Value Range n=
Male [%] 63.4 n = 102/161
Age [years] 49.8612.0 26.4–79.2 n = 160
Weight [kg] 78.0616.4 47.0–149.0 n = 160
BMI [kg/m2] 26.164.9 16.7–45.0 n = 158
CoO Germany [%] 53.1 n = 85
CoO EE/USSR [%] 34.4 n = 55
CoO Mediterranen [%] 8.8 n = 14
CoO Others [%] 3.8 n = 6
HCV RNA [log10 IU/mL] 6.261.1 2.7–8.2 n = 154
ALT [U/L] 68.0693.0 14.0–542.0 n = 152
Cirrhosis [%] 5.6 n = 9/161
Steatosis [%] 29.3 n = 41/140
doi:10.1371/journal.pone.0108751.t002
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Rapid virological response (RVR) was achieved by 573 of all
treated patients while 226 had HCV RNA levels above 15 IU/mL
four weeks after therapy initiation. In the remaining 160
individuals HCV RNA quantification was not performed at week
4 or the sensitivity of the used assays was inadequate to define
RVR (Figure 1). Thus, RVR was achieved in 573/799 (72%). In
patients with GT3, 70% achieved RVR, while this happened more
often in GT2 patients (70% vs. 78%; p = 0.052).
In the RVR group 340 patients achieved SVR, which is
significantly higher compared to patients without RVR (ITT: 59%
vs. 35% and PP: 95% vs. 77%; p,0.0001 for both) (Figure 3A).
RVR was a predictor of SVR irrespective from the present GT 2
or 3 (Figure 3B). Individuals without or inadequate HCV RNA
Table 3. Baseline characteristics of patients with HCV Genotype 3 who started treatment with PegIFN/RBV.
Parameter* Value Range n= p#
Male [%] 66.0 n = 506/767 0.5250
Age [years] 42.269.9 20.1–81.8 n = 761 ,0.0001
Weight [kg] 75.0616.9 40.0–162.0 n = 760 0.0049
BMI [kg/m2] 24.664.7 15.2–57.7 n = 751 ,0.0001
CoO Germany [%] 61.2 n = 447 0.0580
CoO EE/USSR [%] 30.5 n = 223 0.3440
CoO Mediterranen [%] 5.5 n = 40 0.1170
CoO Others [%] 2.7 n = 20 0.4920
HCV RNA [log10 IU/mL] 5.861.0 1.2–8.7 n = 753 0.0007
ALT [U/L] 93.06109.4 11.0–1273.0 n = 745 0.0018
Cirrhosis [%] 8.6 n = 66/769 0.2050
Steatosis [%] 28.6 n = 182/636 0.8740
*Continuous values are indicated in median.
#Chi-Square or t-test results.
CoO = Country of Origin.
doi:10.1371/journal.pone.0108751.t003
Figure 2. SVR rates in all patients with genotypes 2 and 3 (ITT and PP analysis).
doi:10.1371/journal.pone.0108751.g002
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testing at week 4 achieved SVR rates of 31% and 92% in ITT and
PP analysis, respectively. Patients with RVR were significantly
younger (42.1 vs. 48.3 [years]; p,0.0001), had lower HCV RNA
levels (5.8 vs. 6.1 [log 10 IU/mL]; p,0.0001) at baseline and had
less often signs of cirrhosis (6% vs. 11%; p = 0.009) compared to
patients without RVR (Table 4). Interestingly, no differences in
the frequency of steatosis, dose of PegIFN and RBV, respectively,
were observed (Table 4).
Compliance to the current German clinical guideline
According to the German clinical practice guideline patients
chronically infected with hepatitis C virus genotype 2/3 should in
principle be treated for 24 weeks. However, in naı¨ve patients with
low viral load (,800.000 IU/mL and no signs of cirrhosis)
response-guided treatment (RGT) is strongly recommended. If
these patients achieve RVR, a shortening of the treatment
duration to 16 weeks is proposed with a grade A recommendation
[15]. Patients with HCV RNA decline less than 2log10 after 12
weeks of therapy (no EVR) should be stopped immediately [15].
In our cohort, 459 patients fulfilled baseline criteria for RGT
with PegIFN and RBV (Figure 4A). In 24 (3%) individuals HCV
RNA testing was not performed at baseline. Out of 459 patients,
283 (62%) individuals achieved RVR, while 82 (18%) had HCV
RNA levels above 15 IU/mL. Importantly, in 67 (15%) patients
no HCV RNA quantification at week 4 was done. In 27 (6%)
patients assays with low sensitivity were used, thus therapy
shortening could not be decided. Overall, 283 patients treated in
48 centers fulfilled the criteria for RGT according to the German
guideline. Interestingly, only 38 (13%) patients were treated for 16
weeks. In the majority of cases the physicians did not follow the
recommended RGT criteria and patients were treated for 24
weeks (n = 157; 55%) (Figure 4B). Out of the 48 centers, there
were 9 centers with only one patient applicable for RGT. Therapy
shortening was done in 2 out of 9 (22%) individuals. Out of 39
centers with at least 2 patients with option for shortening to 16
weeks only one center treated its patients for 16 weeks. Only 9
(23%) centers considered RGT in at least some of their patients.
Thirty-three out of 39 (85%) centers treated their patients
predominantly for 24 weeks or even longer up to 48 weeks.
Importantly, the SVR rates in the 16-week as well as in the 24-
week cohort were almost similar to more than 90% in the PP
analysis (ITT: 71% vs. 79%; p = 0.294 and PP: 93% vs. 98%;
p = 0.211) (Figure 5A). The same was true for GT3 (Figure 5B).
In addition, we analyzed non-cirrhotic patients with low
baseline viral load who did not achieve RVR. Overall, 82 patients
with low viral load and no signs of cirrhosis at baseline did not
achieve RVR. According to the German guideline these patients
may even be considered for longer treatment based on limited
evidence [15]. In this registry 28 out of 82 (34%) were treated for
24 weeks (Figure 4A). About one third of patients (n = 26; 32%)
received therapy longer than 24 weeks including 10 individuals
treated for 48 weeks. For 15 patients treatment duration was not
assessed. Importantly, the SVR rate was again above 90% in
patients treated for 24 weeks and was comparable to all patients
with RVR (data not shown). Therapy prolongation longer than 24
weeks did not lead to higher SVR rates in this registry with a
relatively low number of patients (Tx 24 weeks 93% vs. Tx.24
weeks 82%; p = 0.3144). All patients, receiving therapy for more
than 12 weeks, achieved EVR. Of note, 46 (7%) patients were not
tested for HCV RNA at week 12.
Also patients with RVR and high viral load at baseline and/or
liver cirrhosis had SVR rate of 94% and were comparable to
patients with low viral load and no signs of cirrhosis (94% vs. 93%;
p = 0.773).
Figure 3. SVR rates according to HCV genotype and week 4 response. A: SVR rates in patients with or without RVR. B: SVR rates in patients
with GT2 or 3 with or without RVR.
doi:10.1371/journal.pone.0108751.g003
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Patients, who were treated with PEGIFN/RBV very efficacy,
were patients with cirrhosis and non-RVR. In our registry only
20% (5/25) in the ITT and 50% (5/10) in the PP analysis achieved
SVR. Median treatment duration was 24 weeks.
Additional costs due to over-treatment
Within our cohort many patients were treated longer than
recommended in the German guideline due to different reasons,
thus additional costs were generated. The majority of patients was
treated with PegIFN-2b and had a mean weight of 77.4 kg. Based
on these findings the approximate therapy costs for four weeks
with 120 mg Peg-IFN-2b (PEGINTRON, MSD Whitehouse
Station, NJ, USA) plus RBV (REBETOL, MSD Whitehouse
Station, NJ, USA) are 2,346 J. In total 210 patients with low viral
load and no signs of cirrhosis were treated longer than
recommended (mean 22 weeks, median 24 weeks), which lead to
additional costs of 897,589 J and 20 individuals with high viral
load and/or signs of cirrhosis but with RVR were treated longer
than 24 weeks (148,637 J) in contrast to the German guideline.
Consequently over-treatment of patients with HCV GT2/3
resulted in further costs of 1,046,222 J in our cohort, 4,549 J
per patient who was treated longer than recommended in
agreement with the German guideline. Of note, 26 patients with
neither high viral load nor signs of cirrhosis but no RVR were
treated longer than 24 weeks, which is based on limited evidence,
resulting in extra costs of 238,344 J.
Discussion
Treatment of chronic hepatitis C is currently an area of
dramatic changes. Since the approval of sofosbuvir (SOF),
interferon free treatment is already available for genotypes 2 and
3 patients and suggested as standard of care by the new AASLD
[17] and EASL guidelines [18]. However, this treatment
revolution may be not available in all areas of the world at the
same time and even if sofosbuvir is available everywhere,
treatment may be not affordable for some health care systems.
Thus it has to be discussed if the old standard of care, PegIFN and
RBV may be considered for certain patients.
Our prospective patient registry revealed several very important
findings: First, in a large, representative real-life cohort with more
than 150 involved centers treatment with PegIFN and RBV was
highly effective in naı¨ve GT2/3 patients who were adherent to
therapy. The overall per protocol analysis showed 91% SVR.
However, in this real-world setting in Germany, the number of
patients with low adherence or lost-to-follow up was high which
resulted in poor intention-to treat SVR of just 49%. Our intention-
to-treat SVR data are slightly lower compared to randomized
trials where well-selected patients have been included by few
Figure 4. Therapy regimens and treatment durations in different groups of patients. A: Patients are divided in three different groups
according to week 4 response and duration of therapy. B: The first group consists of the so called easy to treat patients with low viral load, no
cirrhosis and RVR. In the second group are patients with RVR but high viral load irrespective of stage of liver fibrosis and the last group contains all
patients with non-RVR.
doi:10.1371/journal.pone.0108751.g004
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well-selected study centers [11,13,19]. The recent HepNet
REDD2/3 trial also showed a high discrepancy - 67% SVR
versus 83% in the completer analysis. Also this trial was performed
under real world-conditions involving 51 centers [20]. Reasons for
the discrepancy between PP and ITT results are various.
Treatment discontinuation due to side effects of PegIFN may be
relevant, which call for IFN free therapies. However, in many
cases patients were just non-compliant and did not return during
or after treatment. Another major finding of our study was that
treatment was unnecessarily prolonged or rather not shortened in
a large portion of patients despite clear recommendations stated in
national and international guidelines [15]. Only one center treated
all easy to treat G2/3 patients with RVR for 16 weeks and just one
fourth of centers considered RGT in the majority of patients.
Importantly, over-treatment did not lead to an increase in SVR
rates but may have increased the number of adverse events and
certainly raised the costs of treatment dramatically. This suggests
that the implementation of guidelines still needs to be improved.
HCV therapy is a rapidly moving field and has seen tremendous
changes in the recent years through the approval of different DAA.
In some countries like Germany or the US sofosbuvir is already
available and SOF/RBV 6 PegIFN has become the new standard
of care for most HCV GT2/3 patients and other DAA are already
on the way. We think that our findings are indeed of great
importance for this new era of DAA combination regimens. There
cannot be a doubt that treatment of chronic hepatitis C with DAA
will become highly expensive in most countries. Adherence to the
exact treatment recommendations will be essential. One pill of
sofosbuvir costs about 700 J in Germany or 1,000 US $ in the US
(April 2014). Our data showed that only few centers followed
guidelines very strictly. Current guidelines recommend 12 weeks
SOF/RBV treatment for GT2 and either 24 weeks of SOF/RBV
or 12 weeks of PegIFN/RBV/SOF in GT3 patients [17,18]. If
again treatment is prolonged in only some patients, costs will
increase significantly, which will be an unacceptable burden for
the national health care systems. Certainly, it has been considered
that over-treatment with the IFN free SOF/RBV regimen may be
very tempting due to very low frequency of side effects. Given the
high costs of these modern therapies a dropout of more than 40%
as documented in our study often due to poor compliance may not
be acceptable. However, due to the better tolerability, treatment
adherence may also improve. Nevertheless, the EASL recom-
mends on-treatment HCV RNA testing at week 2 and 4 during
SOF containing regimens to ensure patients adherence [18].
Finally, our data also confirmed that RGT treatment of naı¨ve
GT2/3 patients with low baseline viral load, no cirrhosis and
RVR according to guidelines is possible and lead to high SVR in
patients. Patients who are eligible to RGT and maintain on
PegIFN/RBV therapy achieved SVR in 93%. SVR was not
inferior to longer treatment of 24 weeks and saved 4,692 J per
patient. This may be in particular relevant for GT3 patients who
require 24 weeks of SOF/RBV. About 70% of IFN eligible and
adherent GT3 patients achieved RVR with an SVR rate in.90%
in our study. Similar data have been reported in randomized trials,
i.e. 67% RVR with 85% SVR [19] or 71% RVR with 81%–90%
SVR [13]. These SVR rates in GT3 are not inferior to SVR rates
reported for 24 weeks SOF/RBV [9] or PegIFN/RBV/SOF [21]
but therapy costs are about 50–100,000 J lower per patient
(Table 5). As PegIFN based SOF therapy is recommended by
recent guidelines, it also has to be discussed whether naı¨ve PegIFN
tolerant GT3 patients without cirrhosis and low baseline HCV
RNA ,800,000 IU/mL should be treated with dual PegIFN/
RBV. A pre-selection based on IFNL3 polymorphism may further
increase the number of patients eligible for this approach [22].
Figure 5. SVR rates in patients with RVR treated for 16 or 24 weeks in the overall cohort and in HCV genotype 3 patients. A: All
patients had low viral, no signs of cirrhosis, RVR and were recommended for 16 weeks of treatment. B: All patients had low viral, no signs of cirrhosis,
RVR and were recommended for 16 weeks of treatment.
doi:10.1371/journal.pone.0108751.g005
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Patients without RVR can have low SVR [19] and may require an
intensive treatment, which could be an add-on of SOF for 12
weeks. Recently, it has been shown that PegIFN/RBV plus SOF
for 12 weeks resulted in 83% SVR in 24 difficult to treat GT3
patients from Texas [21]. An RGT approach would reduce
treatment costs by more than 50,000 J per SVR in IFN eligible
naı¨ve patients compared with flat PegIFN/RBV/SOF for 12
weeks (Table 5). However, this approach has not been prospec-
tively evaluated and four weeks longer exposure to PegIFN is
required.
In summary, treatment of naı¨ve patients with genotype 2 and 3
with PegIFN/RBV is highly effective in patients who tolerate
PegIFN and maintain on treatment, especially in patients with low
baseline HCV RNA ,800,000 IU/mL, no cirrhosis and rapid
virological response. Thus this selected group of patients should
still be considered for PegIFN/RBV in particular in healthcare
systems with limited resources even if sofosbuvir is available and
still be co-administered with PegIFN. However, our data show
that the majority of patients who are eligible for shorter treatment
have been treated too long, which resulted in additional
unnecessary costs and possible adverse events. On the other side,
many patients are lost to-follow-up or discontinue treatment,
which result in an overall low intention-to-treat SVR and
especially increase the cost per SVR. If unchanged, overtreatment
and non-compliance will raise the price of SVR to unacceptable
values if SOF or other DAA with comparable costs are used. For
all treatment concepts including IFN free regimens, adherence to
guidelines needs further improvement, as this will not only
optimize the efficacy but also the efficiency of treatment.
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